Nerve Stimulators Market By Type (Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS) and Vagus Nerve Stimulator (VNS)), By Application (Parkinson’s Disease, Chronic Pain, Epilepsy and Depression), By End-User (Trauma Centers, Ambulatory Surgical Centers and Hospital & Clinics) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Nerve Stimulators Market was valued at US$ 7.4 billion in 2024 and is projected to grow at a CAGR of 12.9% to reach US$ 22.4 billion by 2034.

Neurostimulation is a procedure used for therapeutic purposes. It uses an implanted medical device to modulate and modify brain functions, and the equipment used for it is called a neurostimulators. It has been possible to treat a variety of illnesses, including Parkinson's disease, epilepsy, and migraines, with Neurostimulation. Peripheral neuropathies-related intractable pain syndromes can be effectively managed by Neurostimulation, whether it takes the form of intraspinal or peripheral nerve stimulation.

Social restriction measures placed vulnerable individuals—such as those with Parkinson's disease (P.D.) or dystonic patients receiving Deep Brain Stimulation (DBS)—at an increased risk of chronic stress, and their psychiatric and motor symptoms were observed to worsen. Neurostimulators in treating neurologic illnesses facilitate the transmission of electrical stimulation to the targeted areas of the patient's spinal cord, brain, and peripheral nervous system. For example, movement disorders, epilepsy, Parkinson's disease, chronic pain, and depression are among the conditions for which these are specifically utilized in treatment.

A growing elderly population, the launch of high-tech products, the rising demand for add-on therapies, the increasing prevalence of long-term illnesses like migraine and epilepsy, and the existence of unmet medical needs in these disease categories are some of the major factors propelling the industry. The need for minimally invasive operations, external financing for research and development, and the increasing incidence of neurological and lifestyle-related illnesses are further factors driving the market's expansion. However, the cost of these stimulators and the possible difficulties and side effects that could result from them are the main things preventing the target market from expanding during the estimated period of time.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Nerve Stimulators Market Key Drivers:

Increased frequency of neurological diseases  

• The need for efficient treatment choices is fueled by the rising prevalence of diseases like depression, chronic pain, epilepsy, and Parkinson's disease. This increase in the total number of affected individuals shows that improvements in the diagnosis, treatment, and prevention of severe neurological illnesses are not having the desired effect on reversing the effects of worldwide population shifts. Therefore, immediate action is required to lessen this burden.                                       
• For instance, in March 2024, according to a significant new study published in The Lancet Neurology, over 3 billion people globally had a neurological illness in 2021. The analysis of the data from the Global Burden of Disease, Injuries, and Risk Factor Study (GBD) 2021 was assisted by the World Health Organization (WHO). Currently, the most common cause of illness and impairment in the world is neurological disorders. Since 1990, the total quantity of neurological conditions-related sickness, impairment, and premature death (referred to as disability-adjusted life years, or DALYs) has increased by 18%. There is a significant disparity in the availability of treatment: high-income countries have up to 70 times more neurological specialists per 100,000 people than low- and middle-income countries. Over 80% of neurological deaths and health loss occur in low- and middle-income regions.

Increased percentage of elderly individuals

• Physical and functional alterations in older people make them more susceptible to various neurological illnesses. Thus, the need for neurovascular devices, neurovascular embolization, and Neurostimulation devices will increase due to the growing geriatric population base, which will have a significant influence.

Nerve Stimulators Market Restrains:

High prices and dangers associated with Neurostimulation systems  

• The increased cost of Neurostimulation devices is hindering target market expansion. Furthermore, the use of Neurostimulation devices involves a wide range of surgical procedures, which have several dangers in addition to the original ones, including allergies and voice hoarseness. Even while these negative impacts are usually transient, the electrical signals that these gadgets routinely generate have the potential to impede the market's expansion.

Nerve Stimulators Market is segmented based on type, application, end-user, and region.

Type Insights

• Spinal Cord Stimulator (SCS): Spinal cord stimulator (SCS) is a dominating segment of this sector for the target market. An implanted spinal cord stimulator delivers low-voltage electrical signals straight to the spinal cord to alleviate pain. The majority of the time, spinal cord stimulation is utilized when nonsurgical pain management techniques are unable to relieve pain adequately. Thin cables called electrodes and a tiny battery pack resembling a pacemaker make up spinal cord stimulators (the generator). The generator is positioned beneath the skin, typically close to the buttocks or belly, and the electrodes are placed between the spinal cord and the vertebrae (the epidural space). Patients using spinal cord stimulators can use a remote control to send electrical impulses to themselves when they experience discomfort. The antenna and remote control are located externally on the body.
• Deep Brain Stimulator (DBS): A deep brain stimulator (DBS) is an implanted device that stimulates particular brain regions to treat movement disorders such as tremors and Parkinson's. In deep brain stimulation (DBS), electrodes are implanted in specific brain regions. Electrical impulses the electrodes produce alter brain activity to treat specific medical disorders. Under the skin in the upper chest, a pacemaker-like device regulates the amount of stimulation during deep brain stimulation. Under the skin in the upper chest, a pacemaker-like device regulates the amount of stimulation during deep brain stimulation. This gadget is connected to the electrodes in the brain by a wire that passes under the skin.
• Vagus Nerve Stimulator (VNS): A vagus nerve stimulator (VNS) stimulates the left vagus nerve with high-frequency (20–30 Hz) electrical impulses. Therefore, a vagal nerve stimulator (VNS) reduces seizures in individuals with drug-resistant epilepsy by activating vagal nerve afferent fibers that send messages to the brain.

Application Insights               

• Parkinson’s disease: Among the elderly population, Parkinson's disease (P.D.) is a common neurological condition that is intractable. For Parkinson's patients, deep brain stimulation (DBS) is the most often used surgical procedure. A surgeon inserts Thin metal wires into the brain to help manage specific motor symptoms. These wires provide electrical pulses to the brain. DBS usually works best when reducing motor symptoms like tremors, slowness, and stiffness.
• Chronic Pain: A plethora of chronic pain conditions, including limb mononeuropathies, nerve entrapments, peripheral nerve injuries, phantom limb pain, complex regional pain syndrome, back pain, and even fibromyalgia, have been shown to respond well to peripheral nerve stimulation (PNS) in the past few years.
• Epilepsy: Neurostimulation is a new treatment for neuropsychiatric illnesses. The safety and effectiveness of several Neurostimulation techniques for epilepsy have been established or are presently being researched. Recently, DBS trials have been undertaken at several epileptic centers across the globe in various intracerebral areas, including the thalamus, caudate nucleus, sub thalamic nucleus, and medial temporal lobe structures.
• Depression: In many instances in which the depressive symptoms do not entirely go away, people who receive nerve stimulation therapy for depression report notable improvements in their quality of life. One surgical method that can be used to treat patients with depression that is resistant to treatment is vagus nerve stimulation (VNS). The vagus nerve is a nerve that is strung with a stimulating wire that is connected to an implanted pacemaker-like device. The brain's vagus nerve ascends the neck and connects to regions involved in mood regulation there. The vagus nerve receives regular electrical impulses from this device once it is implanted.

End-User Insights

• Trauma Centers: Trauma centres insert stimulators and provide preliminary programming adjustments as part of SCS therapy to manage the discomfort.
• Ambulatory Surgical Centers: Ambulatory surgical centers are growing more capable of performing minimally invasive SCS operations, providing patients with convenience and quicker recovery periods.
• Hospitals and Clinics: Hospitals and clinics are a dominating segment of this sector for the target market. They provide all levels of treatment, including pre-operative assessment, patient preference for implantation techniques, program modifications, and post-operative care. In these facilities, nerve stimulators are employed, depending on the particular use.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Nerve Stimulators Market Regional Insights

• The North American market is estimated to witness a significantly high revenue share over the forecast period, owing to increasing investments in healthcare infrastructure and rising public awareness of cutting-edge medical treatments. With technology enabling them to address the growing demand for better nerve stimulator results, established firms and newcomers are well-positioned to take advantage of these prospects.  
• Asia Pacific market is estimated to witness the fastest revenue share. The swift economic growth of developing nations like China and India and rising healthcare costs support it. Because of the unmet medical needs and unexplored growth prospects in this region, many foreign manufacturers are relocating their manufacturing bases here, contributing to the growth.
• Europe's market is expanding steadily due to a growing neurological disease awareness campaign, an aging population, and a well-established healthcare system in this region.
• Latin America market is an emerging region experiencing expansion due to rising healthcare costs, an increase in the frequency of neurological illnesses, and regional investments in medical technology.
• Middle East & Africa market is in its developmental stages and is witnessing expanding economies, increased healthcare costs, and an increase in the prevalence of neurological illnesses.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Nerve Stimulators Market report based on type, application, end-user, and region:

Nerve Stimulators Market, By Type:

• Spinal Cord Stimulator (SCS)
• Deep Brain Stimulator (DBS)
• Vagus Nerve Stimulator (VNS)

Nerve Stimulators Market, By Application:

• Parkinson’s Disease
• Chronic Pain
• Epilepsy
• Depression

Nerve Stimulators Market, By End-User:

• Trauma Centers
• Ambulatory Surgical Centers
• Hospital & Clinics

Nerve Stimulators Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Nerve Stimulators Market include NeuroPace, Inc., Boston Scientific Corporation, Aleva Neurotherapeutics S.A., Cochlear Ltd., Cyberonics, Inc., Medtronic plc, St Jude Medical, Inc., Synapse Biomedical, Inc., EndoStim, Inc., and Nevro Corporation.

• In April 2023, Synapse Biomedical, Inc. declared that the NeuRx Diaphragm Pacing System (NeuRx DPS) has received FDA approval (PMA) for patients with spinal cord injuries requiring mechanical ventilation. The FDA's strictest requirement for a device marketing application is the PMA.
• In August 2023, Abbott reported that the Proclaim Plus spinal cord stimulation (SCS) system, which incorporates FlexBurst360 therapy, has received approval from the U.S. Food and Drug Administration (FDA). FlexBurst360 therapy, the newest iteration of Abbott's patented BurstDR stimulation, provides pain coverage in six different trunk and limb locations. It makes programming flexible enough to change when a person's needs for therapy change.
• In April 2022, Boston Scientific Corporation (U.S.) obtained FDA certification for its Vercise Neural Navigator, which comes with STIMVIEW XT visualization software. With this technology, doctors can see where patients receiving deep brain stimulation (DBS) and those with Parkinson's disease are with their leads or electrodes in real time.

• NeuroPace, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Boston Scientific Corporation
• Aleva Neurotherapeutics S.A.
• Cochlear Ltd.
• Cyberonics, Inc.
• Medtronic plc
• St Jude Medical, Inc.
• Synapse Biomedical, Inc.
• EndoStim, Inc.
• Nevro Corporation

"*" marked represents similar segmentation in other categories in the respective section.